Positive impactResults
Piramal Pharma Q2 Results: Firm swings to profit as revenue jumps 28%, led by CDMO growth
CNBC-TV18 1 hr ago·27 Oct 2026, 5:34 pm
Piramal Pharma has reported a strong turnaround in the second quarter of fiscal 2027, moving from a loss to a net profit of ₹5.58 crore. This recovery was driven by a 28% increase in revenue to ₹2,617 crore, alongside an expansion in EBITDA margins to 13.3%. The company's Contract Development and Manufacturing Organization (CDMO) business played a key role in this growth.
For investors, the shift from a loss to profit is a significant positive signal, indicating improved operational efficiency and better cost management. The company has also raised its full-year revenue growth guidance to 19–20%, suggesting that the momentum seen in the first half is likely to continue.
Investors should monitor the sustainability of this growth in the coming quarters. Key areas to watch include the performance of the CDMO segment and the company's ability to maintain its improved margins amidst competitive market conditions.
Excerpt from CNBC-TV18
Published On Oct 27, 2026 | 23:02 IST Last Updated On Oct 27, 2026 | 23:04 IST Piramal Pharma returned to profitability and raised its full-year guidance, driven by surging contract manufacturing pipelines and wider operating margins across global facilities. Discover how leadership plans to handle the upcoming…Read the original at CNBC-TV18
Affected stocks
Bullish1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Piramal Pharma (PPLPHARMA).
- Category: Results.
- AI reads the tone as positive (potentially bullish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update for Piramal Pharma worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
